Fact CheckerSign in

NCT06791330Completed

Genome-wide Association Study of Different Types of Diabetes and Construction of Genetic Risk Score

A Type 1 Diabetes Genetic Risk Score Discriminates Between Type 1 Diabetes and Type 2 Diabetes in Chinese

Source: ClinicalTrials.gov · Last updated 24 Jan 2025

Brief summary (registry, in English)

To enhance the genetic profile of T1D patients in China and construct a Chinese-specific GRS and evaluated its ability to differentiate between T1D and controls, as well as between T1D and T2D.

Status (registry)
Completed
Study type
Observational
Enrollment
7000 (actual)
First submitted
20 Jan 2025
Start date
Jan 2010
Primary completion date
Apr 2024
Lead sponsor
Second Xiangya Hospital of Central South University
NCT number
NCT06791330

What you commit to

  • Study type: Observational
  • Participants enrolled: 7000
  • From Jan 2010 to the primary completion date, Apr 2024
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Subjects with the following conditions were excluded: severe gastrointestinal, cardiovascular, cerebrovascular, liver or kidney diseases; other autoimmune diseases; a history of gastrointestinal surgery; tumours; pregnancy; treatments with oral hypoglycaemic agents or immunomodulators; and use of probiotics, prebiotics or antibiotics within one month.

Who the study is looking for

  • All diagnoses for diabetes were required to adhere to the 1999 World Health Organization diabetes diagnosis criteria. Type 1 diabetes mellitus patients needed to meet specific criteria, including insulin dependence in the first 6 months and the presence of at least one designated islet autoantibody: glutamic acid decarboxylase antibody (GADA), protein tyrosine phosphatase antibody (IA-2A) and zinc transporter 8 antibody (ZnT8A). Type 2 diabetes mellitus patients also needed to show negative results for all three islet autoantibodies at onset. Controls were defined as individuals without diabetes or a family history of diabetes within the same geographic area who had normal oral glucose tolerance test results.

Age in the registry: 3 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.